Astena Holdings Co., Ltd.

TSE:8095 Stock Report

Market Cap: JP¥17.2b

Astena Holdings Past Earnings Performance

Past criteria checks 0/6

Astena Holdings's earnings have been declining at an average annual rate of -22.2%, while the Pharmaceuticals industry saw earnings growing at 7.3% annually. Revenues have been declining at an average rate of 5.2% per year.

Key information

-22.2%

Earnings growth rate

-26.0%

EPS growth rate

Pharmaceuticals Industry Growth3.4%
Revenue growth rate-5.2%
Return on equity-10.0%
Net Margin-4.4%
Last Earnings Update30 Nov 2024

Recent past performance updates

Recent updates

Astena Holdings (TSE:8095) Has Affirmed Its Dividend Of ¥9.00

Oct 17
Astena Holdings (TSE:8095) Has Affirmed Its Dividend Of ¥9.00

Astena Holdings Co., Ltd.'s (TSE:8095) Revenues Are Not Doing Enough For Some Investors

Aug 07
Astena Holdings Co., Ltd.'s (TSE:8095) Revenues Are Not Doing Enough For Some Investors

Astena Holdings (TSE:8095) Has Affirmed Its Dividend Of ¥9.00

Mar 04
Astena Holdings (TSE:8095) Has Affirmed Its Dividend Of ¥9.00

Revenue & Expenses Breakdown

How Astena Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TSE:8095 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Nov 2457,993-2,52515,4780
31 Aug 2453,3872,09114,6200
31 May 2453,2182,09314,2480
29 Feb 2452,6251,61714,1630
30 Nov 2351,9841,16214,0440
31 Aug 2353,38218213,6530
31 May 2351,559-58013,7500
28 Feb 2350,136-7613,6080
30 Nov 2249,63657913,5410
31 Aug 2255,5231,21213,9750
31 May 2261,0071,69313,8480
28 Feb 2267,6321,78713,7510
30 Nov 2172,3221,73613,4940
31 Aug 2171,5041,54313,4160
31 May 2170,7582,36612,9400
28 Feb 2167,7452,18512,2990
30 Nov 2065,3411,98311,8130
31 Aug 2062,8151,95711,9400
31 May 2061,4251,23411,5370
29 Feb 2061,4631,38011,2810
30 Nov 1961,6471,53311,0560
31 Aug 1962,3271,53710,9100
31 May 1962,1131,68810,7900
28 Feb 1961,2851,71810,6740
30 Nov 1860,0831,41410,5940
31 Aug 1859,3211,41810,4170
31 May 1858,36899110,3520
28 Feb 1857,84974510,2820
30 Nov 1757,3871,24110,1080
31 Aug 1756,6335679,9500
31 May 1756,3207809,8700
28 Feb 1755,4595089,8610
30 Nov 1655,12189,8920
31 Aug 1654,6542229,9180
31 May 1654,750-2589,8510
29 Feb 1655,174-1389,7610
30 Nov 1555,422-1439,9230
31 Aug 1555,6931489,9230
31 May 1554,92539210,2020
28 Feb 1554,60247510,1710
30 Nov 1454,1454969,9660
31 Aug 1453,6484629,8200
31 May 1453,5287219,4890
28 Feb 1453,0917839,3800

Quality Earnings: 8095 is currently unprofitable.

Growing Profit Margin: 8095 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 8095 is unprofitable, and losses have increased over the past 5 years at a rate of 22.2% per year.

Accelerating Growth: Unable to compare 8095's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 8095 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.6%).

Return on Equity

High ROE: 8095 has a negative Return on Equity (-10.03%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/19 06:28
End of Day Share Price 2025/01/17 00:00
Earnings2024/11/30
Annual Earnings2024/11/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Astena Holdings Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hisaki HatoriMizuho Securities Co., Ltd.